[Risks of secondary circulatory failure at the time of excessive perfusion with vasoconstrictor agents].
D000804:Angiotensin II; D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D001794:Blood Pressure; D002245:Carbon Dioxide / Q000378:metabolism; D004285:Dogs; D004837:Epinephrine; D005260:Female; D006854:Hydrocortisone / Q000627:therapeutic use; D007022:Hypotension / Q000139:chemically induced; D007263:Infusions, Parenteral; D007773:Lactates / Q000097:blood; D008297:Male; D010101:Oxygen Consumption; D010646:Phentolamine / Q000627:therapeutic use; D012769:Shock / Q000139:chemically induced* / Q000188:drug therapy; D014662:Vasoconstrictor Agents / Q000633:toxicity*
D001786:Blood Glucose; D007773:Lactates; D014662:Vasoconstrictor Agents; D000804:Angiotensin II; D002245:Carbon Dioxide; D006854:Hydrocortisone; D004837:Epinephrine; D010646:Phentolamine
Risques de défaillance circulatoire secndaire lors des perfusions excessives de vaso-constricteurs.